First-line treatment for patients with CML in chronic phase: Second-generation TKIs are the therapy of choice

Research output: Contribution to journal › Comment/debate › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{29dc8641c73f406b9542773cc5bae5a5,

title = "First-line treatment for patients with CML in chronic phase: Second-generation TKIs are the therapy of choice",

author = "Jorge Cortes",

year = "2013",

language = "English (US)",

volume = "27",

journal = "Oncology (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "8",

}

TY - JOUR

T1 - First-line treatment for patients with CML in chronic phase

T2 - Second-generation TKIs are the therapy of choice

AU - Cortes, Jorge

PY - 2013

Y1 - 2013

UR - https://www.scopus.com/pages/publications/84881285253

UR - https://www.scopus.com/pages/publications/84881285253#tab=citedBy

M3 - Comment/debate

C2 - 24133826

AN - SCOPUS:84881285253

SN - 0890-9091

VL - 27

JO - Oncology (United States)

JF - Oncology (United States)

IS - 8

ER -